Novartis Deal for Heart Drug Hinges on Succeeding Where Rivals Struggle
With a planned $9.7 billion deal, Novartis is making a high-stakes bet that the Swiss health-care giant will succeed where many have struggled: launching a new heart drug.
Jared S. Hopkins
The $9.7 billion Novartis deal turns on a quirk of how drugs are paid for in the U.S.: Insurers have less control over drugs given in hospitals than pharmacies
I think the
acquisition is also sending a clear signal that
is not afraid of transforming itself by investing heavily in very innovative therapeutic approaches (siRNA here)